Discovery of novel anti-diabetic drugs by targeting lipid metabolism

Xiu Zhou, Jun Xu, Yuguang Shi, Ji Ming Ye

Producción científica: Articlerevisión exhaustiva

12 Citas (Scopus)


Accumulation of toxic lipids is the most common etiology of insulin resistance in type 2 diabetes and associated metabolic disorders such as obesity and non-alcoholic fatty liver disease. Understanding of the underlying mechanisms has revealed various opportunities to target key regulators in lipid metabolic pathways for the treatment of metabolic diseases. Here, we review the discovery and development of potential anti-diabetic drugs with primary effects on cellular targets leading to reductions of intracellular lipids in key organs. We will particularly focus on AMPK, SIRT1, PGC-1α, SREBP-1c, ChREBP, ACC, PPARs and HSPs which either stimulate in fatty acid oxidation (energy expenditure) or inhibit de novo lipogenesis.

Idioma originalEnglish (US)
Páginas (desde-hasta)1372-1380
Número de páginas9
PublicaciónCurrent drug targets
EstadoPublished - nov 1 2015
Publicado de forma externa

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Clinical Biochemistry
  • Pharmacology


Profundice en los temas de investigación de 'Discovery of novel anti-diabetic drugs by targeting lipid metabolism'. En conjunto forman una huella única.

Citar esto